Adil Adatia, MD

Adil Adatia, MD: University of Alberta

Articles by Adil Adatia, MD

HCPLive Five at AAAAI 2026

ByMatthew Krantz, MD,Sayantani Sindher, MD,Jose Clemente, PhD,Joseph K. Han,Adil Adatia, MD

March 11th 2026

This HCPLive Five captures 5 interviews conducted on-site at AAAAI 2026.

Navenibart at 3- and 6-Month Dosing Reduces HAE Attacks, With Adil Adatia, MD

ByAdil Adatia, MD

March 6th 2026

Phase 2 ALPHA-SOLAR data presented at AAAAI 2026 show navenibart provides >95% median attack reduction in HAE with favorable safety for 3- and 6-month prophylaxis.

HCPLive Five at ACAAI 2025

ByPrincess Ogbogu, MD,David Golden, MD,Amber Luong, MD, PhD,Adil Adatia, MD,Druhan Howell, MD

December 9th 2025

This HCPLive Five features advancements in asthma, immunology, and allergy that were presented at the ACAAI 2025 meeting in Orlando.

Sebetralstat Shows Promise for On-Demand HAE Treatment in Children, With Adil Adatia, MD

ByAdil Adatia, MD

November 13th 2025

At ACAAI 2025, Adatia discussed interim KONFIDENT-KID trial findings showing oral sebetralstat safely reduced symptom burden in pediatric HAE.

Adil Adatia, MD

Articles by Adil Adatia, MD

HCPLive Five at AAAAI 2026

Navenibart at 3- and 6-Month Dosing Reduces HAE Attacks, With Adil Adatia, MD

HCPLive Five at ACAAI 2025

Sebetralstat Shows Promise for On-Demand HAE Treatment in Children, With Adil Adatia, MD

Latest Updated Articles

Trending on HCPLive

Interim Phase 3 VISIONARY Data Show Sibeprenlimab Preserved Kidney Function in IgA Nephropathy

Navigating a New Era of PH Management as an APP, With Susanne McDevitt, DNP

First Half 2026 Recap: Dermatology

From Red-Cheeked Baby to Bulbous Nose: Rosacea, Start to Finish

Guideline-Directed Care Improves Limb Outcomes in Peripheral Artery Disease